LRRK2 Mutations and Asian Disease-Associated Variants in the First Parkinson's Disease Cohort from Kazakhstan

被引:7
|
作者
Kaiyrzhanov, Rauan [1 ]
Aitkulova, Akbota [2 ]
Shashkin, Chingiz [3 ]
Zharkinbekova, Nazira [3 ]
Rizig, Mie [1 ]
Zholdybayeva, Elena [2 ]
Jarmukhanov, Zharkyn [2 ]
Akhmetzhanov, Vadim [3 ]
Kaishibayeva, Gulnaz [4 ]
Khaibullin, Talgat [5 ]
Karimova, Altynay [4 ]
Akshulakov, Serik [6 ]
Bralov, Askhat [6 ]
Kissamedenov, Nurlan [6 ]
Seidinova, Zhanar [3 ]
Taskinbayeva, Anjela [3 ]
Muratbaikyzy, Aliya [3 ]
Houlden, Henry [1 ]
机构
[1] UCL, Inst Neurol, Dept Neuromuscular Disorders, Queen Sq, London WC1N 3BG, England
[2] Natl Ctr Biotechnol, Dept Mol Genet, 13-5 Korgalzhyn Ave, Nur Sultan 01000, Kazakhstan
[3] South Kazakhstan Med Acad, Dept Neurol, 1-1 Al Farabi Ave, Shymkent 160019, Kazakhstan
[4] Inst Neurol, 9a Mamur 4 Microdist, Alma Ata 050000, Kazakhstan
[5] Semey Med Univ, Dept Neurol, 103 Abai St, Semey 071400, Kazakhstan
[6] Natl Ctr Neurosurg, 34-1 Turan Ave, Nur Sultan 01000, Kazakhstan
基金
英国医学研究理事会; 英国惠康基金;
关键词
RISK-FACTOR; GLY2385ARG VARIANT; SUSCEPTIBILITY; CHINESE; GENE; G2019S;
D O I
10.1155/2020/2763838
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background. LRRK2 mutations have emerged as the most prevalent and potentially treatable determinants of Parkinson's disease (PD). Peculiar geographic distribution of these mutations has triggered an interest in genotyping PD cohorts of different ethnic backgrounds for LRRK. Objective. Here, we report on the results of LRRK2 screening in the first Central Asian PD cohort. Methods. 246 PD patients were consecutively recruited by movement disorder specialists from four medical centers in Kazakhstan, and clinicodemographic data and genomic DNA from blood were systematically obtained and shipped to the Institute of Neurology University College London together with DNAs from 200 healthy controls. The cohort was genotyped for five LRRK2 mutations (p.Gly2019Ser, p.Arg1441His, p.Tyr1699Cys, p.Ile2020Thr, and p.Asn1437His) and three East Asian disease-associated variants (p.Gly2385Arg, p.Ala419Val, and p.Arg1628Pro) via Kompetitive allele-specific polymerase chain reaction assay analysis. Results. None of the study subjects carried LRRK2 mutations, whereas the following Asian variants were found with insignificant odds ratios (OR): p.Gly2385Arg (1.2%, minor allele frequency (MAF) 0.007, OR 1.25, p=0.8), p.Ala419Val (3.7%, MAF 0.02, OR 1.5, p=0.4), and p.Arg1628Pro was found only in 1% of controls. p.Gly2385Arg was positive in a big family with PD and tremor, although with incomplete segregation. One early-onset PD subject was homozygous for p.Ala419Val who developed fast progression and severe dyskinesias. p.Ala419Val was associated with early-onset PD. Conclusions. We showed that East Asian LRRK variants could be found in Central Asian populations but their pathogenicity remains to be elucidated in larger PD cohorts.
引用
收藏
页数:10
相关论文
共 50 条
  • [42] Genetic analysis of LRRK2 mutations in patients with Parkinson's disease
    Deng, H
    Le, W
    Guo, Y
    Hunter, C
    Xie, W
    Jankovic, J
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S361 - S362
  • [43] Mitochondrial impairment in Parkinson's disease patients with LRRK2 mutations
    Arns, B.
    Meier, B.
    Klein, C.
    Gruenewald, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 846 - 846
  • [44] LRRK2 mutations are a common cause of Parkinson's disease in Spain
    Mata, IF
    Ross, OA
    Kachergus, J
    Huerta, C
    Ribacoba, R
    Moris, G
    Blazquez, M
    Guisasola, LM
    Salvador, C
    Martinez, C
    Farrer, M
    Alvarez, V
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (04) : 391 - 394
  • [45] SCREENING FOR LRRK2 MUTATIONS IN UK SPORADIC PARKINSON'S DISEASE
    Lewthwaite, A. J.
    Lambert, T. D.
    Marley, F. E.
    Nicholl, D. J.
    Clarke, C. E.
    Morrison, K. E.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (04): : 462 - 462
  • [46] Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease
    Ito, Genta
    Utsunomiya-Tate, Naoko
    BIOMOLECULES, 2023, 13 (05)
  • [47] An overview of the worldwide distribution of LRRK2 mutations in Parkinson's disease
    El Otmani, Hicham
    Daghi, Mohamed
    Tahiri Jouti, Nadia
    Lesage, Suzanne
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2023, 13 (06) : 335 - 350
  • [48] MIBG scintigraphy in Parkinson's disease with and without LRRK2 mutations
    Masso, J. F. Marti
    Martinez, J. Ruiz
    Bolano, M. J.
    Gorostidi, A.
    Marras, C.
    de Munain, A. J. Lopez
    MOVEMENT DISORDERS, 2008, 23 (01) : S254 - S255
  • [49] Pathophysiological Heterogeneity in Parkinson's Disease: Neurophysiological Insights from LRRK2 Mutations
    Kojovic, Maja
    Kassavetis, Pangiotis
    Parees, Isabel
    Georgiev, Dejan
    Rocchi, Lorenzo
    Balint, Betina
    Foltynie, Tom
    Rothwell, John
    Bhatia, Kailash
    MOVEMENT DISORDERS, 2017, 32 (09) : 1333 - 1335
  • [50] Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease:: identification of two novel LRRK2 variants
    Xiromerisiou, G.
    Hadjigeorgiou, G. M.
    Gourbali, V.
    Johnson, J.
    Papakonstantinou, I.
    Papadimitriou, A.
    Singleton, A. B.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (01) : 7 - 11